Our results suggest that ALKBH5, as a biomarker for predicting anti PD-L1 immunotherapy outcomes in NSCLC patients, is a potential target for addressing anti PD-L1 immunotherapy resistance in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.